Despite a drop-off in deal numbers, 2019 was a great year for biopharma IP owners
Last year’s M&A and licensing figures suggest that there is a sellers' market in many types of life sciences assets
To read more
Register for limited access
Register to receive our weekly newsletter and access two of our subscriber-only articles per month.
Register now
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.
Subscribe now